Bristol Financial Ratios Analysis
| BMY Stock | USD 48.30 0.46 0.96% |
Bristol |
Most ratios from Bristol Myers' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Bristol Myers Squibb current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Bristol Myers Valuation and Bristol Myers Correlation analysis. At this time, Bristol Myers' Free Cash Flow Per Share is fairly stable compared to the past year. Net Income Per Share is likely to rise to 4.07 in 2024, whereas Dividend Yield is likely to drop 0.04 in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Dividend Yield | 0.0317 | 0.0302 | 0.0447 | 0.0374 | Price To Sales Ratio | 2.99 | 3.32 | 2.36 | 2.98 |
Bristol Myers fundamentals Correlations
Click cells to compare fundamentals
Bristol Myers Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Bristol Myers fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 4.19 | 3.29 | 2.99 | 3.32 | 2.36 | 2.98 | |
| Ptb Ratio | 2.12 | 3.7 | 3.85 | 4.93 | 3.61 | 6.92 | |
| Book Value Per Share | 30.26 | 16.75 | 16.18 | 14.58 | 14.22 | 14.94 | |
| Free Cash Flow Yield | 0.0588 | 0.0661 | 0.0949 | 0.11 | 0.078 | 0.13 | |
| Invested Capital | 0.92 | 1.37 | 1.27 | 1.31 | 1.41 | 1.48 | |
| Pb Ratio | 2.12 | 3.7 | 3.85 | 4.93 | 3.61 | 6.92 | |
| Ev To Sales | 5.53 | 4.17 | 3.67 | 4.0 | 3.03 | 3.11 | |
| Inventory Turnover | 1.88 | 5.68 | 4.74 | 4.33 | 4.02 | 2.54 | |
| Net Income Per Share | 2.02 | (3.98) | 3.15 | 2.97 | 3.88 | 4.07 | |
| Payables Turnover | 3.3 | 4.34 | 3.37 | 3.33 | 3.28 | 3.81 | |
| Capex To Revenue | (0.032) | (0.0177) | (0.021) | (0.0242) | (0.0269) | (0.0282) | |
| Cash Per Share | 9.03 | 7.01 | 7.75 | 4.34 | 5.94 | 6.23 | |
| Pocfratio | 13.57 | 9.97 | 8.54 | 11.73 | 7.66 | 7.28 | |
| Interest Coverage | 8.33 | 3.61 | 7.62 | 8.38 | 14.79 | 20.34 | |
| Payout Ratio | 0.53 | 0.78 | (0.45) | 0.63 | 0.73 | 0.59 | |
| Pfcf Ratio | 15.14 | 10.53 | 9.09 | 12.83 | 8.39 | 8.81 | |
| Income Quality | 2.33 | (1.56) | 2.31 | 2.06 | 1.72 | 1.02 | |
| Roe | 0.0666 | (0.24) | 0.19 | 0.2 | 0.27 | 0.3 | |
| Pe Ratio | 31.82 | (15.57) | 19.8 | 24.22 | 13.23 | 19.89 | |
| Ev To Free Cash Flow | 20.0 | 13.32 | 11.17 | 15.47 | 10.76 | 11.3 | |
| Earnings Yield | 0.0583 | 0.0314 | (0.0642) | 0.0413 | 0.0756 | 0.0536 | |
| Current Ratio | 5.22 | 1.6 | 1.58 | 1.25 | 1.43 | 1.96 | |
| Receivables Turnover | 3.78 | 3.4 | 5.0 | 3.71 | 3.31 | 2.95 |
Pair Trading with Bristol Myers
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bristol Myers position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bristol Myers will appreciate offsetting losses from the drop in the long position's value.Moving together with Bristol Stock
| 0.77 | A | Agilent Technologies Financial Report 28th of May 2024 | PairCorr |
| 0.62 | EQ | Equillium Financial Report 9th of May 2024 | PairCorr |
Moving against Bristol Stock
| 0.62 | KA | Kineta Inc Financial Report 9th of May 2024 | PairCorr |
| 0.6 | DMTK | DermTech Financial Report 2nd of May 2024 | PairCorr |
| 0.56 | DRUG | Bright Minds Biosciences | PairCorr |
| 0.51 | ME | 23Andme Holding | PairCorr |
| 0.46 | VALN | Valneva SE ADR Financial Report 2nd of May 2024 | PairCorr |
The ability to find closely correlated positions to Bristol Myers could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bristol Myers when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bristol Myers - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bristol Myers Squibb to buy it.
The correlation of Bristol Myers is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bristol Myers moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bristol Myers Squibb moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bristol Myers can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Bristol Myers Valuation and Bristol Myers Correlation analysis. You can also try the AI Investment Finder module to use AI to screen and filter profitable investment opportunities.
Complementary Tools for Bristol Stock analysis
When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |
Is Bristol Myers' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bristol Myers. If investors know Bristol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bristol Myers listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.09) | Dividend Share 2.31 | Earnings Share 3.86 | Revenue Per Share 21.753 | Quarterly Revenue Growth 0.006 |
The market value of Bristol Myers Squibb is measured differently than its book value, which is the value of Bristol that is recorded on the company's balance sheet. Investors also form their own opinion of Bristol Myers' value that differs from its market value or its book value, called intrinsic value, which is Bristol Myers' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bristol Myers' market value can be influenced by many factors that don't directly affect Bristol Myers' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bristol Myers' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bristol Myers is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bristol Myers' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.